Lin Yang
Associate Director Alloy Therapeutics
Lin Yang is the Associate Director of Discovery at Alloy Therapeutics, where she leads multidisciplinary efforts to identify and advance novel therapeutic candidates. With deep expertise in antibody engineering and directed evolution, Lin oversees early-stage discovery programs from target validation through lead optimization. Her team leverages multiple display platforms to discover highly functional protein binders that align closely with each program’s target product profile. Before joining Alloy, Lin was a postdoctoral fellow in Dr. Sai Reddy’s group at ETH Zürich, where she led research integrating AI/ML with directed evolution to accelerate antibody discovery. Lin earned her PhD in Chemical and Biomolecular Engineering in Dr. Jamie Spangler’s lab at Johns Hopkins University, where her research focused on antibody engineering.
Seminars
- T cell receptor mimic antibodies enable therapeutic targeting of intracellular antigens through peptide MHC complexes that are inaccessible to conventional antibodies
- Discovery is challenging due to the need for extreme specificity across closely related peptide MHC epitopes, modest binding affinities, and preservation of native peptide presentation during screening
- Integrating high diversity immune libraries with advanced mammalian cell sorting using target expressing cells to identify potent, selective, and developable TCRm antibodies
- Display platforms enable detailed mapping of peptide specificity, while AI/ML guided protein engineering accelerates optimization of affinity, selectivity, safety, and developability from early binders to therapeutic candidates
